| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, July 31, 2017 When Express Scripts unveils its national preferred formulary each year, industry watchers immediately look to its decisions for clues about trends in the drug business. It’s no different this year, with several exclusions—or a lack thereof in some fields—indicating where things are headed. |
|
|
Top Stories Of The Week Monday, July 31, 2017 AstraZeneca and MedImmune, still reeling from a combo survival failure of its new immuno-oncology meds in lung cancer, have hired a clutch of new cancer R&D execs. Thursday, August 3, 2017 Teva will lay off 7,000 employees, exit dozens of markets by the end of this year and close 15 plants in the next two years as it tries to offset a deteriorating generics market that has gut-kicked sales of the generics leader. Thursday, August 3, 2017 Tucked away in the middle of its second-quarter results today, Regeneron announced that it and long-term Big Pharma partner Sanofi will end their antibody research partnership before 2018. Wednesday, August 2, 2017 Tell physicians something they don’t know. That’s one of the key messages that came from the ePharma Physicians annual study, in which doctors claimed 51% of the time, sales reps are showing them redundant information during visits. Monday, July 31, 2017 After months of rumors and amid a larger flurry of CRO M&A activity, LabCorp has bought out U.K. CRO Chiltern. Both have been on the M&A trail of late, with LabCorp buying CRO Covance in 2015 for $6 billion while midsize CRO Chiltern has also been beefing itself up over the years. Wednesday, August 2, 2017 Right on the heels of Express Scripts’ 2018 formulary release, rival PBM giant CVS Caremark has published its list of which drugs are in and which are out. Monday, July 31, 2017 Boston Scientific is set to scrap its bioresorbable stent program, Star Tribune reports. The decision to can the program before getting a full look at its study data follows a succession of setbacks for Abbott’s rival stent that have dented the sector’s hopes of generating big sales. Tuesday, August 1, 2017 For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas of business struggled. Vaccines outperformed other units at GlaxoSmithKline and Sanofi, while Merck’s immunizations posted double-digit growth. Wednesday, August 2, 2017 Scientists at the University of Michigan wanted to understand what makes solid tumors spread—and how personalized drugs could best be employed in patients whose cancers have metastasized. So they did a far more detailed genetic analysis of tumors than commercially available tests could provide. | This week's sponsor is Salesforce. | | | [Webinar] Accelerate Clinical Trials with Rapid Application Development
Wednesday, August 9 | 2pm ET / 11am PT
Join this session to learn how biopharmaceutical companies are building connected applications for clinical development that give all stakeholders a common view of the trial.. Register Now! |
|
